Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

INTRODUCTION: Cutaneous adverse events (AEs) have been observed in clinical studies of daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis (RRMS). Here, we report cutaneous AEs observed in the randomized, double-blind, active-comparator DECIDE study (ClinicalTrials.gov iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Krueger, James G., Kircik, Leon, Hougeir, Firas, Friedman, Adam, You, Xiaojun, Lucas, Nisha, Greenberg, Steven J., Sweetser, Marianne, Castro-Borrero, Wanda, McCroskery, Peter, Elkins, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939160/
https://www.ncbi.nlm.nih.gov/pubmed/27251051
http://dx.doi.org/10.1007/s12325-016-0353-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939160/
https://www.ncbi.nlm.nih.gov/pubmed/27251051
http://dx.doi.org/10.1007/s12325-016-0353-2

Ejemplares similares